Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA – the EU medicines regulator) has today given a positive recommendation for the extension of the marketing authorisation for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least 1 prior…

Read more

EMA CHMP gives positive opinion on CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myeloma

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has given a positive recommendation for the extension of the marketing authorisation for idecabtagene vicleucel (ide-cel), a CAR-T treatment marketed by BMS as Abecma®. Ide-cel is currently approved for the treatment of patients with relapsed and refractory myeloma, who have…

Read more

EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation

The European Medicines Agency (the EU medicines regulator) Committee for Medicinal Products for Human Use (CHMP) has today confirmed their earlier recommendation to not renew marketing authorisation for belamaf mafadotin (Blenrep®). The confirmation follows a review of the CHMP decision, requested by the manufacturer GSK. MPE Co-Chief Executive Officer, Kate Morgan, commented: “The final recommendation…

Read more

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to…

Read more
February

March 2026

April
MO
TU
WE
TH
FR
SA
SU
23
24
25
26
27
28
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Events for 1st March
No Events
Events for 2nd March
No Events
Events for 3rd March
No Events
Events for 4th March
No Events
Events for 5th March
No Events
Events for 6th March
No Events
Events for 7th March
No Events
Events for 8th March
No Events
Events for 9th March
No Events
Events for 10th March
No Events
Events for 11th March
No Events
Events for 12th March
No Events
Events for 13th March
No Events
Events for 14th March
No Events
Events for 15th March
No Events
Events for 16th March
No Events
Events for 17th March
No Events
Events for 18th March
No Events
Events for 19th March
No Events
Events for 20th March
No Events
Events for 21st March
No Events
Events for 22nd March
No Events
Events for 23rd March
No Events
Events for 24th March
No Events
Events for 25th March
No Events
Events for 26th March
No Events
Events for 27th March
No Events
Events for 28th March
No Events
Events for 29th March
No Events
Events for 30th March
No Events
Events for 31st March
No Events